Our findings will contribute to the development of therapeutic strategies targeting EPHA3 to mitigate the aggressiveness of HCC, leveraging the ability to quantitatively detect alterations in VIM-AS1 expression and changes in DNA methylation levels at the VIM-AS1 locus. This evidence concerns the gene VIM-AS1 and hepatocellular carcinoma.